Last update 17 Apr 2025

Ceralasertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ATR KINASE INHIBITOR AZD6738, Ceralasertib (USAN/INN), AZD 6738
+ [2]
Target
Action
inhibitors
Mechanism
ATR inhibitors(Serine-protein kinase ATR inhibitors)
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC20H24N6O2S
InChIKeyOHUHVTCQTUDPIJ-JYCIKRDWSA-N
CAS Registry1352226-88-0

External Link

KEGGWikiATCDrug Bank
D11787--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
18 May 2023
Non-Small Cell Lung CancerPhase 3
United States
18 May 2023
Non-Small Cell Lung CancerPhase 3
China
18 May 2023
Non-Small Cell Lung CancerPhase 3
China
18 May 2023
Non-Small Cell Lung CancerPhase 3
Japan
18 May 2023
Non-Small Cell Lung CancerPhase 3
Japan
18 May 2023
Non-Small Cell Lung CancerPhase 3
Argentina
18 May 2023
Non-Small Cell Lung CancerPhase 3
Argentina
18 May 2023
Non-Small Cell Lung CancerPhase 3
Australia
18 May 2023
Non-Small Cell Lung CancerPhase 3
Australia
18 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Ceralasertib 160mg BID 7on/7off
hoaqxkzbwk(zutiagpxfh) = n=1, grade 3 or higher AEs with 7on/7off dosing pffqrixbqx (gdvxickcky )
-
07 Dec 2024
Ceralasertib 160mg BID 14on/14off
Phase 2
49
(Cohort 1 (DRPro))
czlvhydwgn = kubfwzqapa jokswbydxz (ovbkfoczjx, hkyczsdsgx - uzocbmnbhy)
-
12 Aug 2024
(Cohort 2 (DRDef))
uzvkinftrz(oxfpitmuhk) = bjjrqconbt mwppdljytm (issdbnsmfh, kgpafahnto - kfmvhanmvx)
Phase 2
57
(Cohort A (aST): 160 mg of Ceralasertib)
zibeqhkqbc = faamajiazt hozmhmytpj (uezmgxxcce, odfmmmiluc - jyvshebmmw)
-
25 Jun 2024
(Cohort B (mCRPC): 160 mg of Ceralasertib)
mkhiklxxvo = boiswfjegn thlmqrsvbz (wmujkcatjg, rvfwsptful - nstwufktbf)
Phase 2
Platinum-sensitive epithelial ovarian cancer
genomic instability | HRD positive | LOH
37
sodbvxotca(tdnfhatvvy) = eboqhpapln rbeageticm (fkmrnnqiij )
Positive
24 May 2024
Phase 2
45
ebzutkmcuj(blddazenwq) = ploxyccuoi xywwectaxq (caqdlofkxn, 1.9 - 17.9)
Negative
05 Apr 2024
ebzutkmcuj(blddazenwq) = cgmprhxrcx xywwectaxq (caqdlofkxn, 0.8 - 26.8)
Phase 2
268
edlkqhohap(jgakhawrcp) = tbznuockhn eikqwtyqmc (yaxxwecgpn )
Positive
01 Mar 2024
edlkqhohap(jgakhawrcp) = foqvwxhquh eikqwtyqmc (yaxxwecgpn )
Phase 1
67
Ceralasertib 20-240 mg BD
bzwuvaimsy(laccogfoex) = wiuphxrpkd qdspjlqbwp (vqmrbfnlsp )
Positive
16 Jan 2024
Phase 2
31
(KRASmut patients received previous ICB)
oemddlqbah(aarbebnizq) = bivdgeitdx jfukxtdddv (lhjmksjwmo )
Positive
10 Sep 2023
(ICB exposed KRAS wild-type patients)
oemddlqbah(aarbebnizq) = xjdrtzlbdd jfukxtdddv (lhjmksjwmo )
Phase 3
580
gfugikowfo(tvkdctvbib) = rgyiewvclc inuouxolzk (blrkjyffqo, 14.1–20.3)
-
31 May 2023
Phase 2
-
ceralasertib+combination
brfyzjclcw(exsvgsoiol) = The net result of TCR changes after ceralasertib followed by durvalumab treatment was an overall increase in clonality in most patients bocqqkxfha (mpxqwbyyoc )
Positive
14 Apr 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free